@entity2857 combined with percutaneous radiofrequency ablation for the treatment of medium-sized XXXX .

@entity1 @entity39 @entity294 @entity2857 @entity157 @entity1054
OBJECTIVE: @entity2857 , an oral multikinase inhibitor, is the proved therapy method for @entity1 with @entity157 ( @entity157 ). Based on heat delivery, Radiofrequency ablation (RFA) has been found to achieve @entity39 . It is the most widely performed percutaneous therapy for @entity157 . However, Study associated combined @entity2857 with RFA therapy for @entity1 with advanced @entity157 has never been reported. The aim of present study is to explore the efficacy and safety of @entity2857 combined with RFA therapy for the @entity1 with medium-sized @entity157 . @entity1 AND METHODS: A total of 62 @entity1 diagnosed as @entity157 were involved in this study. All @entity1 were randomly assigned to @entity2857 and RFA (n=30) or RFA-alone (n=32) treatment groups. Treatment outcomes, including recurrence rates, @entity1054 ( @entity1054 ) and adverse reactions induced by @entity2857 were observed and recorded to assess the efficacy and safety of the combination method. RESULTS: During the overall follow-up period, the recurrence rate of the combination subgroup was 56.7% (17/30), and that of the RFA-alone subgroup was 87.5% (28/32) (p < 0.01). The median @entity1054 was 17.0 months in the combination therapy vs. 6.1 months in the RFA-alone (p < 0.05). Hand-foot skin reactions were reported by 83.3% (25/30) of @entity1 and 46.7% (14/30) reported @entity294 while the most adverse events (AEs) were mild to moderate in the combination subgroup. CONCLUSIONS: @entity2857 combined with RFA significantly decreased recurrence rates and prolonged the survival time of medium-sized @entity157 @entity1 . The combination therapy is safer and more effective than the control without unexpected side effects. Furthermore, the earlier application, the better results were.
